http://pubs.jamanetwork.com/ en-us Wed, 01 May 2013 00:00:00 GMT Wed, 01 May 2013 15:46:03 GMT Silverchair editor@pubs.jamanetwork.com webmaster@pubs.jamanetwork.com http://pubs.jamanetwork.com/article.aspx?articleID=1684843 Wed, 01 May 2013 00:00:00 GMT Ramirez-Fort MK, Doan HQ, Nguyen HP, et al. 1 1 10.1001/jamadermatol.2013.3358 http://pubs.jamanetwork.com/article.aspx?articleID=1684843 http://pubs.jamanetwork.com/article.aspx?articleID=1684844 Wed, 01 May 2013 00:00:00 GMT 2 2 10.1001/jamadermatol.2013.3358a http://pubs.jamanetwork.com/article.aspx?articleID=1684844 http://pubs.jamanetwork.com/article.aspx?articleID=1684846 Wed, 01 May 2013 00:00:00 GMT Summers EM, Bingham CS, Dahle KW, et al. <span class="paragraphSection"><div class="boxTitle">Importance</div>Dermatologists frequently encounter patients of advanced age presenting with chronic eczematous eruptions of uncertain etiology. When a drug-induced cutaneous eruption is suspected, identifying the responsible drug(s) is a complex clinical challenge.<div class="boxTitle">Objective</div>To determine whether certain drug classes, and in particular calcium channel blockers, are associated with chronic eczematous eruptions in the aging (CEEA) in the United States.<div class="boxTitle">Design</div>Retrospective case-control study.<div class="boxTitle">Setting</div>Ambulatory patients from the Department of Dermatology, University of Utah School of Medicine, Salt Lake City.<div class="boxTitle">Patients</div>The cases consisted of 94 patients 50 years and older presenting with otherwise unexplainable symmetrical eczematous eruptions of at least 2 months' duration between January 1, 2005, and December 31, 2011. Inclusion criteria also included histopathologic changes of spongiotic and/or interface dermatitis and clinical suspicion for a drug-induced cutaneous eruption. The controls consisted of 132 age-, sex-, and race-matched patients presenting with benign dermatologic conditions. A subgroup analysis on cases whose skin biopsy specimens showed a pattern of inflammation that is conventionally thought to be associated with eczematous drug eruptions (ie, eczematous and interface dermatitis) was also performed.<div class="boxTitle">Main Outcomes and Measures</div>Specific drug classes associated with otherwise unexplainable CEEA.<div class="boxTitle">Results</div>A statistically significant difference in drug class use between cases and controls for calcium channel blockers and thiazides was noted. For calcium channel blockers and thiazides, the matched odds ratios were 4.21 (95% CI, 1.77-9.97; P = .001) and 2.07 (95% CI, 1.08-3.96; P = .03) respectively. The histopathological pattern subgroup analysis failed to show any statistically significant associations.<div class="boxTitle">Conclusions</div>The findings of this study further support an association of calcium channel blockers, as well as thiazides, with CEEA in the United States.</span> 1 5 10.1001/jamadermatol.2013.511 http://pubs.jamanetwork.com/article.aspx?articleID=1684846